Ovarian Rejuvenation ACT: The Science, the Evidence, and Realistic Expectations | ALIV

Ovarian rejuvenation — the application of autologous growth factors, concentrated platelets, or cell-derived preparations to the ovary to support follicular function — is one of the most discussed and most emotionally charged topics in Indian reproductive medicine. Women with diminished ovarian reserve (DOR), premature ovarian insufficiency (POI), or poor response to ovarian stimulation during IVF are told by one provider that "ovarian rejuvenation" is the answer and by another that it is unproven. ALIV's approach, led by Dr. Sunita Tandulwadkar, is grounded in the most honest possible reading of the current evidence: the science is plausible, early results are promising in selected patients, and the expectations must match the evidence quality.

The Scientific Rationale

The ovary contains granulosa cells (which support follicle development), thecal cells (which produce androgens that granulosa cells convert to oestrogen), and a poorly characterised population of ovarian progenitor cells that may support new follicle formation from germline stem cells — a possibility that remains scientifically contested. The microenvironment of the ovary — the balance of growth factors, inflammatory signals, and vascular supply — profoundly affects follicular survival and development. In DOR and POI, this microenvironment is impaired: reduced VEGF reduces ovarian blood supply; elevated FSH reflects inadequate follicular development; reduced AMH reflects a shrinking antral follicle pool.

The growth factors in ALIV's ovarian ACT preparation — VEGF (improving ovarian angiogenesis), PDGF (supporting granulosa cell function), IGF-1 (supporting folliculogenesis), and anti-inflammatory signals (reducing the follicular microenvironment's inflammatory burden) — address this microenvironmental impairment directly. The mechanism is not controversial; the question is whether the magnitude of the biological effect is sufficient to produce clinically meaningful improvement in women with significantly compromised ovarian reserve. See: ACT for infertility and reproductive health.

What the Evidence Shows

The most cited evidence for autologous ovarian platelet-rich plasma (PRP — a related autologous approach using peripheral blood platelets rather than bone marrow or adipose-derived cells) comes from a series of case reports and small studies showing AMH improvement and successful pregnancies in women with POI who had previously failed ovarian stimulation. A Greek group (Sfakianoudis et al.) published the most discussed series — small numbers, no randomised control group, but striking individual cases. Independent replication is limited. The honest assessment: the evidence is promising, not proven; selected patients respond, most do not achieve dramatic reserve restoration; and the procedure in experienced hands carries minimal procedural risk given its autologous nature. This is the clinical-evidence framing ALIV applies to every ovarian rejuvenation consultation.

Who is the ideal ovarian rejuvenation candidate?

Women most likely to show a response: DOR with some residual follicular activity (AMH above 0.3 ng/mL, AFC above 2–3 on ultrasound); age under 42 (older women have more significantly compromised follicular pools); failed IVF from poor response but not absolute zero eggs; and willingness to engage with a complete fertility evaluation to understand all contributing factors before the procedure. Women with absolute POI (AMH undetectable, no AFC, menopausal FSH levels persisting over multiple cycles) are the group least likely to show a meaningful response, though ALIV's clinical team is transparent about this in the pre-procedure consultation rather than excluding this group categorically.

How does ALIV's ovarian ACT differ from standard PRP ovarian treatment?

Standard PRP ovarian treatment uses concentrated platelets from peripheral blood — relatively high in PDGF, VEGF, and TGF-β. ALIV's ovarian ACT preparations use MSC-derived growth factors from bone marrow or adipose tissue, which provide a broader paracrine profile including HGF and IGF-1 alongside the platelet-derived factors. The mechanistic rationale for a richer growth factor profile is plausible; whether it translates to meaningfully better clinical outcomes than standard PRP in this specific application requires head-to-head clinical data that does not yet exist. ALIV's approach reflects the best current clinical reasoning, not proven superiority over PRP.